Tactile Medical (TCMD): Company Cash Volume

Is it worth investing in Tactile Systems Technology (TCMD), given its dependence on insurance reimbursements and sales efficiency? The cash position provides the answer, and its current level is 0.07. Business margins are constrained by distribution costs and new therapy methods. Growth is driven exclusively by expanding the sales force without engaging in M&A transactions.
Summary analytical data breakdowns for tactilemedical.com (TCMD)

Assessing the investment risks of Tactile Systems Technology (TCMD) requires an analysis of liquidity as the fundamental basis for stability. Stable demand for lymphedema therapy generates a predictable cash inflow, which is reflected in the cash_co metric. This cash dynamics within the company measures the volume of available capital relative to market value, revealing the actual asset density. A growing reserve balance confirms the effectiveness of the business model and minimizes the probability of hidden capital outflows.